



ASX Announcement
30 January 2023

OPTISCAN PARTNERS WITH PROLUCID TECHNOLOGIES TO DEVELOP AI ALGORITHMS

Optiscan Imaging Limited (ASX: OIL) is pleased to announce an exclusive collaboration with **Prolucid Technologies**, to develop Artificial Intelligence (AI) algorithms and telepathology workflows using its confocal laser endomicroscopy (CLE) technology.

The project, anticipated to take 18-24 months including a series of key developmental milestones, will take images from Optiscan's platform technology, and develop a processing pipeline that will display results of an AI algorithm to clinicians for immediate decision-making during clinical workflows. The application will be used by trained healthcare professionals in a variety of hospital and clinical settings, with a focus on oral imaging and cancer detection in the first instance.

The partnership with the Ontario-based software developer has been established to further enhance the clinical capability of Optiscan's technology, with the goal of developing a Software as a Medical Device (SaMD) application that will support image collection, processing, and tissue analytics to detect the presence of pre-cancerous and cancerous cells.

"We are excited to commence this exclusive collaboration with Optiscan in the field of Artificial Intelligence," said Darcy Bachert, Chief Executive Officer of Prolucid Technologies. "The capability of Optiscan's imaging technology, combined with our software development capability, aims to transform how healthcare professionals detect cancer. We are excited to be collaborating with Optiscan on this project and delivering value for their customers."

Optiscan CEO and Managing Director, Dr. Camile Farah stated, "The development of AI algorithms using our technology supports our vision to be at the forefront of enabling immediate, informed clinical decisions for healthcare professionals globally using digital microscopy. We are delighted to be partnering with Prolucid Technologies on this cutting-edge innovation project, which will help clinicians achieve the best possible patient outcomes through the earlier detection, diagnosis and treatment of cancer."

– ends –

This announcement has been authorised for release by the Board of Optiscan.

For investor queries, please contact:

Dr. Camile Farah

Chief Executive Officer & Managing Director – Optiscan Imaging Ltd

E: cfarah@optiscan.com

About Optiscan

Optiscan Imaging Ltd (ASX:OIL) is a global leader in the development, manufacturing, and commercialisation of confocal endomicroscopic imaging technologies for medical, translational and pre-clinical applications. Our technology enables real-time, non-destructive, 3D, *in-vivo* imaging at the single-cell level.

We are driven by developing technology and its use to give healthcare providers and researchers the highest quality real-time microscopic imaging tools to enable the early detection and management of disease, improve patient outcomes, and reduce the high cost of curative medicine and associated procedures.

Our patent-protected proprietary technology, using specially miniaturised componentry, has created a pen-sized digital microscope, which can be used on any tissue it contacts to produce high resolution digital pathology images for cancer diagnosis and surgical margin detection in real-time. The aim of our technology development is for earlier diagnosis and subsequent treatment of cancerous tumours with expected associated improved patient outcomes.

About Prolucid Technologies

Prolucid is an ISO-13485 certified software engineering company based in Ontario (Canada) that specializes in custom software development for medical devices and systems. For over 14 years we have helped successfully bring a wide variety of imaging, diagnostic, analytics, and cloud connected medical technologies to market for customers ranging from startups to large multinationals.

Our services include custom embedded, desktop, cloud, and mobile application development, that include data collection, analytics and powerful visualisations.

We support from ideation through design, prototyping, and full-market commercialization, while integrating best practices with software development, cyber-security, data privacy and protection, as well as relevant quality and regulatory standards, greatly simplifying, and de-risking project execution.

Disclaimer

All statements other than statements of historical fact included on this announcement including, without limitation, statements regarding future plans and objectives of Optiscan or any of the other parties referred to herein, are forward-looking statements. Forward-looking statements can be identified by words such as 'anticipate', 'believe', 'could', 'estimate', 'expect', 'future', 'intend', 'may', 'opportunity', 'plan', 'potential', 'project', 'seek', 'will' and other similar words that involve risks and uncertainties. These statements are based on an assessment of present economic and operating conditions, and on assumptions regarding future events and actions that are expected to take place. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of the Company, its directors and management of Optiscan that could cause actual results to differ from the results expressed or anticipated in these statements.

P: (61 3) 9538 3333

A: 16 Miles St, Mulgrave VIC 3170, Australia

W: www.optiscan.com